Virtual Event | August 24, 2022

DCTs And Sites: What Sponsors Need To Know

Source: YPrime

When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or cancelled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics and to the patients, seemed to be the solution to keep things on track.

But where do your sites stand on DCTs? Do they fully understand what they are and how they will impact the financial landscape? Are they a blessing or a curse to site personnel? Clinical Leader Live sat down with three site experts to discuss the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more. As sites continue to struggle with the migration to DCTs, do your sites love or hate them, how do they feel about the sponsors they work with, and what can you do about it?

access the Virtual Event!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader